Most Popular Choices
Share on Facebook 54 Printer Friendly Page More Sharing
OpEdNews Op Eds    H2'ed 12/9/18

Drug Company Execs Make Millions Misleading Cancer Patients. Here's One Way to Stop Them

By       (Page 1 of 1 pages)   2 comments
Message Sam Pizzigati
Become a Fan
  (2 fans)

From Counterpunch

Anatomy of a Cancer Treatment Scam
Anatomy of a Cancer Treatment Scam
(Image by YouTube, Channel: FTCvideos)
  Details   DMCA

Cancer kills. Every American knows that.

What every American doesn't know: Cancer is also helping some Americans become exceedingly rich. And these Americans will do most anything to keep their windfalls coming, even prey on the fragile psyches of the families cancer strikes.

Top cancer treatment centers, the consumer group Truth in Advertising charges in a new report, are "deceptively promoting atypical patient experiences through the use of powerful testimonials." Back in 2005, U.S. cancer centers spent $54 million showcasing these deceptive testimonials. By 2014, that annual outlay had more than tripled to $173 million.

One typical testimonial in this advertising barrage features an effusively grateful patient named Carl, a pancreatic cancer survivor. The ad never mentions that pancreatic cancer five-year survival rates run just 8.5 percent.

"Any cancer center can find a patient who has beat the odds," notes the new Truth in Advertising report, The Deceptive Marketing of Hope. "But using that atypical experience to prey on the hopes and fears of such a susceptible patient population has real consequences."

Cancer patients deciding where to go for treatment, for instance, may be so impressed by a testimonial that they stop looking for treatment alternatives and travel out of state, ignoring "closer, better, or less expensive options" much closer to home.

Misleading marketing is working exceedingly well -- for the top brass at the for-profit cancer centers that now dot the American health care landscape, outfits like the Cancer Treatment Centers of America chain. This company has relocated its headquarters to Boca Raton, a prime South Florida wealth magnet.

The CEO who engineered this relocation, a former luxury hotel executive, celebrated the move by picking up a new $2 million waterfront home.

The company's current chairman, Richard Stephenson, has found the cancer treatment business particularly rewarding. This Illinois mega-millionaire, Johns Hopkins University biomedicist Steven Salzberg points out, has used "the profits from his cancer hospitals to support his favorite right-wing causes." In 2012 alone, Stephenson poured $12 million into the Tea Party.

The bad actors pumping out misleading cancer treatment ads also include, somewhat surprisingly, many of the nation's most prominent cancer-treatment not-for-profits. The most celebrated of these, the Memorial Sloan Kettering Cancer Center in New York, shelled out $11.7 million last year marketing testimonials from survivors like "Joanne S.," a stage-four lung cancer patient. Such patients overall have a 4.7 percent survival rate.

Misleading cancer patients pays quite handsomely for nonprofit executives, too. Memorial Sloan Kettering CEO Craig Thompson pulled down $6.7 million from his day job in 2016 and nearly another $600,000 last year serving on the corporate boards of two pharmaceutical companies.

Outrageously excessive executive pay, numbers like these suggest, amounts to an economic "carcinogen" -- a cancer-causing agent that first takes hold in the for-profit private sector, then spreads throughout our body politic, corrupting everything it touches.

The best way to protect against this corruption? We could start by leveraging the power of the public purse against enterprises that pay out excessive executive rewards.

Lawmakers, for instance, could deny subsidies to companies that pay their top executives over 25 times what their typical workers are making. A move along that line would have stopped the Cancer Treatment Centers of America chain from qualifying for $2.4 million in state and local government subsidies when the company relocated to Boca Raton.

America's big-time corporate execs currently average over 350 times what average workers are taking home. We may not ultimately be able to vanquish cancer. But we can certainly vanquish the CEO pay excess that so exploits cancer's victims.

Must Read 1   Supported 1   Valuable 1  
Rate It | View Ratings

Sam Pizzigati Social Media Pages: Facebook page url on login Profile not filled in       Twitter page url on login Profile not filled in       Linkedin page url on login Profile not filled in       Instagram page url on login Profile not filled in

Veteran labor journalist and Institute for Policy Studies associate fellow Sam Pizzigati co-edits Inequality.org, the Institute's weekly newsletter on our great divides. He also contributes a regular column to OtherWords, the IPS national nonprofit editorial service.

Sam, now retired from the labor movement, spent two decades directing the publishing program at America's largest union, the (more...)
 

Go To Commenting
The views expressed herein are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.
Writers Guidelines

 
Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles
Support OpEdNews

OpEdNews depends upon can't survive without your help.

If you value this article and the work of OpEdNews, please either Donate or Purchase a premium membership.

STAY IN THE KNOW
If you've enjoyed this, sign up for our daily or weekly newsletter to get lots of great progressive content.
Daily Weekly     OpEd News Newsletter
Name
Email
   (Opens new browser window)
 

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

How to Stop a Tax Plan Rigged for the Rich

Getting Granular on America's Income Distribution

The Flacks for Plutocrats Need a New Analogy

Trump's EPA Is A Huge Cancer Risk

New York, New York, What a Less than Wonderful Town

Billionaires Won't Save the World, Just Look at Elon Musk

To View Comments or Join the Conversation:

Tell A Friend